Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Co-Diagnostics

Fulgent Genetics

Inovio Pharmaceuticals

Arcturus Therapeutics

Investors in fast-moving biotechs made out like bandits.

These Were the 5 Top Genetics Stocks of 2020

AstraZeneca

Johnson & Johnson

If you can afford to invest the money, these stocks could help you make the most of it.

3 Stocks That Could Double Your $600 Stimulus Check

CAMBRIDGE, Mass. & STOCKHOLM--(BUSINESS WIRE)--Recipharm and Moderna finalize agreement for aseptic drug product manufacturing and fill-finish for supply to countries outside the U.S.

Recipharm and Moderna Finalize Agreement for Aseptic Drug Product Manufacturing and Fill-Finish for Supply to Countries Outside the U.S.

This smaller biotech company attracted a lot of attention in 2020, but is it still worth an investment?

Moderna's Stock Has Surged 488% in 2020: Is It a Buy for 2021?

Moderna Inc (NASDAQ: MRNA) announced a worker vaccination plan as an extra layer of COVID-19 protection for its employees in the United States on Tuesday. What Happened: The biotech company said that its coronavirus vaccine will be made available to its workers, contractors, and board members under the FDA emergency use authorization.

Moderna Makes COVID-19 Vaccine Available To Board, Staff, And Contractors On Priority

Moderna — the pharmaceutical company which produced one of the two COVID-19 vaccines with emergency authorization from the Food and Drug Administration — said on Tuesday that it would offer its COVID-19 vaccine to employees, contractors, and board members. In a news release, the company said that the move, which could be at odds with the Center for Disease Control and Prevention's priority groups, was "to provide an additional layer of COVID-19 protection." "Moderna is making its vaccine available to its workers, contractors, and board members in the US under Emergency Use Authorization. The program will extend to adult household members of our team to reduce the risk of absenteeism and disruption due to a COVID-19 infection in an adult household member," the statement said, including that participation would be confidential and voluntary.

Moderna's board members and adults in their households will be among first in line to take their vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna confirms discussions with the Government of South Korea to supply South Korea with 40 million doses of COVID-19 Vaccine.

Moderna Confirms Discussions With the Government of South Korea to Supply South Korea With 40 Million Doses of COVID-19 Vaccine

Following the FDA approval of its vaccine, MRNA stock is set to make some big gains on distribution deals across the globe. The post Moderna Is a Great Investment Despite Short-Term Headwinds appeared first on InvestorPlace.

Moderna Is a Great Investment Despite Short-Term Headwinds

Fate Therapeutics

Mersana Therapeutics

Intellia Therapeutics

Ultragenyx Pharmaceutical

Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.

5 Biotech Stocks That Have Gained More Than 200% in 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to present at the Goldman Sachs 13th Annual Healthcare CEOs Unscripted Conference: A View from the Top.

Moderna to Present at the Goldman Sachs 13th Annual Healthcare CEOs Unscripted Conference: A View from the Top

Moderna's stock has declined by roughly 25% over the last two weeks. While news from the company has been largely positive, with its Covid-19 vaccine receiving emergency approval from the U.S. FDA and dosing starting in the U.S., the decline in the stock is likely largely technical.

Why Moderna Stock Is Down 25% In Recent Weeks

Pfizer

Mutations could mean more money for the two drugmakers.

Why New Coronavirus Strains Could Boost Pfizer and Moderna's Fortunes

Moderna Inc (NASDAQ: MRNA) has agreed to supply South Korea its COVID-19 vaccine, with doses enough for 20 million people, reports Yonhap News Agency.  What Happened: Cheong Wa Dae — the South Korean presidential office — and Moderna CEO Stephane Bancel arrived at a revised agreement virtually on Monday, as per Yonhap.

Moderna Agrees To Supply South Korea With COVID-19 Vaccine For 20M People: Yonhap

Investors were apparently spooked by news of one patient's allergic reaction following inoculation.

Why Moderna Stock Dove by Nearly 10% on Monday

Moderna was able to develop what proved to ve a successful COVID-19 vaccine over a weekend, thanks to Messenger RNA technology it had been working on for a decade. The post Here's Why Moderna Stock Could Be the Stock of the Decade appeared first on InvestorPlace.

Here's Why Moderna Stock Could Be the Stock of the Decade

Cost and logistics will determine the ultimate winner.

Moderna or Pfizer? Which Company Stands to Gain the Most From Vaccine Rollout

BioNTech SE

Novavax

Telesis Bio Inc

Vaxart

We discuss six biotech/drug stocks, NVAX, VXRT, MRNA, TBIO, INO and BNTX that have more than doubled in 2020 on the back of their progress in coronavirus vaccine development.

6 Biotech/Drug Stocks Up Manifold in 2020 Thanks to COVID-19

As the world is threatened by the prospects of the SARS-CoV-2 mutating to produce new virulent strains, Moderna Inc (NASDAQ: MRNA) has reassured there isn't a cause for concern. What Happened: The vaccine-induced immunity from Moderna's coronavirus vaccine candidate – mRNA-1273 - will likely be protective against the new strain of SARS-CoV-2 recently described in the U.K., the Massachusetts-based company said in a late Wednesday statement.

Moderna Says Coronavirus Vaccine's Effectiveness Will Likely Hold Against New SARS-CoV-2 Variants

Moderna says it's confident that its COVID-19 vaccine will provide protection from the highly contagious coronavirus strain that's spreading in the UK and other countries. Research has shown the shot is “equally effective” against several other variants of the virus that emerged earlier in the pandemic, the Massachusetts biotech firm said in a statement.

Moderna confident COVID-19 vaccine will work against new strain

Both biotech companies' vaccines have received approval for emergency use in the U.S. -- but which is a better coronavirus stock?

Better Coronavirus Stock: Moderna or Pfizer?

Their success definitely isn't guaranteed, but the biotech just might make billions of dollars from these candidate treatments.

Meet Moderna's Most Likely Blockbusters After Its COVID Vaccine

Coronavirus vaccine stocks yo-yoed Wednesday as Pfizer won a deal for 100 million more doses in the U.S. and Moderna snagged authorization in Canada for people ages 18 and older. The post Vaccine Stocks Rebound On Pfizer's U.S. Deal, Moderna OK In Canada appeared first on Investor's Business Daily.

Vaccine Stocks Rebound On Pfizer's U.S. Deal, Moderna OK In Canada

AGCO

Brandywine Realty

Brookfield Property REIT

Enphase Energy

Fastly

HD Supply Hlds

NortonLifeLock

NRG Energy

Insulet

Rockwell Automation

Tesla

Unum

Zoom Video

These are the stocks with the best value, fastest growth, and most momentum for January.

Top Stocks for January 2021

Investors who enjoyed a five-fold return this year are selling now but more upside approaches as Moderna ships vaccines worldwide. The post Moderna Stock Looks Too Cheap After This Recent Dip appeared first on InvestorPlace.

Moderna Stock Looks Too Cheap After This Recent Dip

Shares of Moderna Inc. were down 0.1% in trading on Wednesday after it said Canada authorized its COVID-19 vaccine for adults. The government there has committed to buying 40 million doses of the vaccine, which requires two doses for each person.

News for Moderna Stock (MRNA)